title: [Challenge of neuroborreliosis].
abstract: Lyme borreliosis is the most frequent tick-borne infection in Europe. It is a multisystemic disease affecting the skin, joints, heart, in rare cases the eyes and regularly the nervous system. Taking current clinical and microbiological guidelines into account, neuroborreliosis can in general be diagnosed and treated successfully. An appropriate guideline-conform antibiotic treatment is effective and in most cases recovery from acute neuroborreliosis is complete. Nevertheless, the evidence base regarding pharmacological treatment needs reform and improvement. Contrary to this scientifically based medical opinion, divergent opinions presented in the media cause uncertainty and confusion among patients and also some physicians. The currently available scientific data on epidemiology, treatment and performance of microbiological testing reveals gaps and therefore a large scope for interpretation. In clinical practice, diagnostics and therapeutic methods that do not fulfill the criteria of evidence-based medicine are widely used due to the uncertain data situation. The Clinical Network Neuroborreliosis (KNN) is a publicly funded network of clinicians and clinical laboratory physicians with the goal to improve knowledge for disease-oriented evaluation of diagnostic and therapeutic methods. In addition, the Robert Koch Institute (RKI) and the KNN are performing an epidemiological study for collation and estimation of the number of neuroborreliosis cases in Germany (aNBorD study).
authors.affiliation: Klinik und Poliklinik für Neurologie, Universitätsmedizin der Johannes Gutenberg-Universität, Langenbeckstraße 1, 55131, Mainz, Deutschland. annette.spreer@unimedizin-mainz.de.
authors.forename: A
authors.initials: A
authors.lastname: Spreer
authors.affiliation: Neurologische Universitätsklinik, Freiburg, Deutschland.
authors.forename: S
authors.initials: S
authors.lastname: Rauer
authors.affiliation: Gastrointestinale Infektionen, Zoonosen und tropische Infektionen, Infektionsepidemiologie, Robert Koch-Institut, Berlin, Deutschland.
authors.forename: H
authors.initials: H
authors.lastname: Wilking
authors.affiliation: Nationales Referenzzentrum für Borrelien, Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, Oberschleißheim, Deutschland.
authors.forename: V
authors.initials: V
authors.lastname: Fingerle
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001898:Borrelia / Q000187:drug effects*; D003937:Diagnosis, Differential; D019317:Evidence-Based Medicine; D005858:Germany; D006801:Humans; D020852:Lyme Neuroborreliosis / Q000134:cerebrospinal fluid / Q000175:diagnosis* / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents
keywords: Antibiotics; Borrelia burgdorferi; Cerebrospinal fluid; Clinical Network Neuroborreliosis; Tick-borne infection